Table 4 Logistic regression of dose escalation status and treatment year adjusting for potential confounders in NODA during Period 2 (2010–2013)
NODA 2010–2013 (N = 567) | ||||
|---|---|---|---|---|
Study sample characteristics | Escalated dose | Standard dose | Escalated vs standard dose | |
No. (%) | No. (%) | Adjusted OR (95% CI) | P* | |
Treatment year | 0.78 (0.66–0.91) | 0.0018 | ||
Age | ||||
≤ 67 yo | 112 (54) | 239 (50) | ref | |
> 67 yo | 97 (46) | 235 (50) | 0.86 (0.61–1.21) | 0.39 |
Sex | ||||
Male | 129 (62) | 274 (58) | ref | |
Female | 80 (38) | 200 (42) | 0.81 (0.57–1.14) | 0.23 |
Race | ||||
White | 181 (86) | 394 (82) | ref | |
Non-white | 28 (13) | 80 (17) | 0.70 (0.42–1.12) | 0.14 |
Missing | 2 (1) | 3 (1) | Not included | |
Histology | ||||
Squamous | 111 (53) | 228 (48) | ref | |
Non-Squamous | 98 (47) | 246 (52) | 0.79 (0.56–1.12) | 0.18 |
Derived AJCC v6 T-stage | ||||
T0-2 | 144 (69) | 313 (66) | ref | |
T3 | 65 (31) | 154 (33) | 0.88 (0.61–1.26) | 0.49 |
Missing | 0 (0) | 7 (1) | Not included | |
Charlson/Deyo Score | ||||
0 | 132 (63) | 294 (62) | ref | |
1 | 56 (27) | 127 (27) | 0.99 (0.67–1.46) | 0.98 |
2+ | 21 (10) | 53 (11) | 0.93 (0.52–1.61) | 0.80 |
Hospital typea | ||||
Community | 160 (77) | 405 (85) | ref | |
Academic | 49 (23) | 69 (15) | 1.96 (1.27–3.49) | 0.0047 |
Hospital settinga | ||||
Metro | 174 (80) | 412 (87) | ref | |
Non-metro | 35 (20) | 62 (13) | 2.07 (1.20–3.01) | 0.0024 |